June 24, 2025 — On the closing day of the ADA Scientific Sessions in Chicago, we got a good look at two remarkable new obesity drugs. Both of them have potential to bring important advances. Both of them need more work before they will be ready to go to FDA for approval. This was a rare treat. Bimagrumab The […]
June 23, 2025 — With two new publications in the New England Journal of Medicine, we are thinking that CagriSema has something to teach us about using weight loss outcomes to judge the merits of a new obesity medicine. Is more always better? Researchers presented the data from these two pivotal clinical trials on CagriSema at the ADA Scientific […]
June 20, 2025 — We are landing in Chicago for the ADA Scientific Sessions and you can be sure that a veritable river of news about obesity will be flowing. Everything from basic science to innovative treatment and pragmatic approaches for clinical care and policy will be offered up by this meeting of the American Diabetes Association. This promises […]
May 19, 2025 — Obesity care is in the midst of an awkward but critical transition. Standards of care for obesity are leaking out from specialists in obesity medicine through a process of translation to the setting of primary care for the masses. Primary care for obesity will draw upon the authoritative work of organizations like Obesity Canada, The […]
September 27, 2024 — After a day of a National Obesity Policy Forum at the Top of the Hill in Washington, it was plain that we have witnessed a profound shift in the conversation about policy to address obesity. No more lip service about nudging America to “eat healthy” as the answer to a high prevalence of this disease. […]
June 21, 2023 — We’re packing our bag for San Diego and the 83rd Scientific Sessions of the American Diabetes Association, which starts on Friday. This is not a meeting that has been a regular habit for ConscienHealth. But this year it seems ADA2023 will be another milestone in the ongoing diabesity merger. That almost too clever term first […]
December 13, 2022 — The American Diabetes Association is out with their new standards of care for 2023 and at the top of the list of seven major changes is a refined focus on obesity. Changes in medical care are subtle and slow. But when you look at how it has evolved over recent years, the shift in views […]
June 6, 2022 — Two ideas are hard to miss at the annual Scientific Sessions of the American Diabetes Association. One is that it’s getting harder to treat and prevent diabetes adequately without treating obesity. Second is that health systems can’t handle this reality. They are systematically preventing adequate obesity and diabetes care. Distinct but Overlapping Diseases Let’s get […]
June 5, 2022 — This is what you might call a clean sweep. At the Scientific Sessions of the ADA and in NEJM yesterday, researchers unveiled detailed data on tirzepatide for obesity. When Lilly gave us a peek at these data a month ago, “Wow!” was our response. With the full details in view and peer reviewed, we tend […]
June 14, 2019 — It was odd. Lilly had a promising new drug for diabetes that delivered unusually good weight outcomes. But they weren’t sure about developing it for obesity. That was last October. Now, though, they seem to have decided to move ahead with their dual GIP/GLP-1 agonist, tirzepatide, for obesity. Pivotal phase 3 trials will begin this […]
